Investor Area

Home / Investor Area / News / CLINUVEL accredits first European EPP expert centres
 

CLINUVEL accredits first European EPP expert centres

 13 March 2016

 

CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its European commercial team is conducting site training and accreditation at the first of the European expert porphyria centres this week. Following training these centres of expertise will be accredited to prescribe CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) to adult patients diagnosed with erythropoietic protoporphyria (EPP).

 

Download PDF for more